RSNA 2021 Digital X-Ray Preview

DSM-TACE is safe when nothing else works

By Will Morton, staff writer

Tuesday, November 30 | 9:30 a.m.-10:30 a.m. | SSIR02-5 | Room TBA
This interventional radiology session will provide information on a German study that evaluated the safety and efficacy of transarterial chemoembolization with degradable starch microspheres (DSM-TACE) for patients with unresectable hepatocellular carcinoma (HCC). The patients had high tumor burden and were ineligible for or were failing other palliative therapies.

The researchers retrospectively analyzed data on 121 patients with high tumor burden and more than three HCC nodules in vascular invasion treated at three European centers between 2009 and 2018; 558 treatments were performed. Modified Response Evaluation Criteria in Solid Tumors (mRECIST) were used for response assessment.

The best response after DSM-TACE was seen after a median of three treatments, with complete response, partial response, stable disease, and progressive disease noted in 13.5%, 44.5%, 25.2%, and 16.8% of patients, respectively. DSM-TACE was well tolerated with no major clinical adverse events, the study authors found.

In addition, after repetitive DSM-TACE, the researchers observed preserved liver function in patients even when the liver was treated as a whole.

"Repetitive DSM-TACE can be performed safely with low adverse event rates and liver function preservation over time," concluded Dr. Johannes Ludwig and colleagues. Ludwig, a radiologist at University Hospital Essen, will present the research.

What do you do when nothing else works? Check out this Tuesday morning session for the details.

Last Updated np 11/15/2021 4:04:45 PM